Maxearn

Maxvax (formerly Maxearn) is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, focused on the development of next-generation vaccines and novel adjuvants. The company utilizes its proprietary adjuvant technology platform to create recombinant vaccines targeting infectious diseases with high global burdens, including shingles, rotavirus, and HPV. Its lead candidate, MAV-001, is a recombinant shingles vaccine currently in Phase 2 clinical trials, designed to offer a potent alternative to existing products. Maxvax integrates research, development, and large-scale manufacturing to ensure the accessibility and affordability of its immunization products. The company is backed by prominent investors such as Hillhouse Capital and Sequoia China, supporting its mission to address unmet medical needs in the vaccine space.